Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2010

01.07.2010 | Epidemiology

Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer

verfasst von: Jenny Chia-Yun Wu, Matti Hakama, Ahti Anttila, Amy Ming-Fang Yen, Nea Malila, Tytti Sarkeala, Anssi Auvinen, Sherry Yueh-Hsia Chiu, Hsiu-Hsi Chen

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Estimating the natural history parameters of breast cancer not only elucidates the disease progression but also make contributions to assessing the impact of inter-screening interval, sensitivity, and attendance rate on reducing advanced breast cancer. We applied three-state and five-state Markov models to data on a two-yearly routine mammography screening in Finland between 1988 and 2000. The mean sojourn time (MST) was computed from estimated transition parameters. Computer simulation was implemented to examine the effect of inter-screening interval, sensitivity, and attendance rate on reducing advanced breast cancers. In three-state model, the MST was 2.02 years, and the sensitivity for detecting preclinical breast cancer was 84.83%. In five-state model, the MST was 2.21 years for localized tumor and 0.82 year for non-localized tumor. Annual, biennial, and triennial screening programs can reduce 53, 37, and 28% of advanced cancer. The effectiveness of intensive screening with poor attendance is the same as that of infrequent screening with high attendance rate. We demonstrated how to estimate the natural history parameters using a service screening program and applied these parameters to assess the impact of inter-screening interval, sensitivity, and attendance rate on reducing advanced cancer. The proposed method makes contribution to further cost-effectiveness analysis. However, these findings had better be validated by using a further long-term follow-up data.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Tabar L, Fagerberg G, Chen HH, Duffy SW, Smart CR, Gad A, Smith RA (1995) Efficacy of breast cancer screening by age. Cancer 75:2507–2517CrossRefPubMed Tabar L, Fagerberg G, Chen HH, Duffy SW, Smart CR, Gad A, Smith RA (1995) Efficacy of breast cancer screening by age. Cancer 75:2507–2517CrossRefPubMed
2.
Zurück zum Zitat Chen HH, Duffy SW, Tabar L, Day NE (1997) Markov chain models for progression of breast cancer. Part I: tumour attributes and the preclinical screen-detectable phase. J Epidemiol Biostat 2:9–23 Chen HH, Duffy SW, Tabar L, Day NE (1997) Markov chain models for progression of breast cancer. Part I: tumour attributes and the preclinical screen-detectable phase. J Epidemiol Biostat 2:9–23
3.
Zurück zum Zitat Chen HH, Duffy SW, Tabar L, Day NE (1997) Markov chain models for progression of breast cancer. Part II: prediction of outcomes for different screening regimes. J Epidemiol Biostat 2:25–35 Chen HH, Duffy SW, Tabar L, Day NE (1997) Markov chain models for progression of breast cancer. Part II: prediction of outcomes for different screening regimes. J Epidemiol Biostat 2:25–35
4.
Zurück zum Zitat Lai MS, Yen MF, Kuo HS, Koong SL, Chen THH, Duffy SW (1998) Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases: Taiwan multicentre cancer screening (TAMCAS). Int J Cancer 78:21–26CrossRefPubMed Lai MS, Yen MF, Kuo HS, Koong SL, Chen THH, Duffy SW (1998) Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases: Taiwan multicentre cancer screening (TAMCAS). Int J Cancer 78:21–26CrossRefPubMed
5.
Zurück zum Zitat Tabar L, Fagerberg G, Chen HH, Duffy SW, Smart CR, Gad A, Smith RA (1995) Efficacy of breast cancer screening by age. Cancer 1995:2507–2517CrossRef Tabar L, Fagerberg G, Chen HH, Duffy SW, Smart CR, Gad A, Smith RA (1995) Efficacy of breast cancer screening by age. Cancer 1995:2507–2517CrossRef
6.
Zurück zum Zitat Weedon-Fekjær H, Vatten LJ, Aalen OO, Lindqvist B, Tretli S (2005) Estimating mean sojourn time and screening test sensitivity in breast cancer mammography screening: new results. J Med Screen 12:172–178CrossRefPubMed Weedon-Fekjær H, Vatten LJ, Aalen OO, Lindqvist B, Tretli S (2005) Estimating mean sojourn time and screening test sensitivity in breast cancer mammography screening: new results. J Med Screen 12:172–178CrossRefPubMed
8.
Zurück zum Zitat Wu JC, Anttila A, Yen AM, Hakama M, Saarenmaa I, Sarkeala T, Malila N, Auvinen A, Chiu SY, Chen THH (2009) Evaluation of breast cancer service screening programme with a Bayesian approach: mortality analysis in a Finnish region. Breast Cancer Res Treat (in press). doi:10.1007/s10549-009-0604-x Wu JC, Anttila A, Yen AM, Hakama M, Saarenmaa I, Sarkeala T, Malila N, Auvinen A, Chiu SY, Chen THH (2009) Evaluation of breast cancer service screening programme with a Bayesian approach: mortality analysis in a Finnish region. Breast Cancer Res Treat (in press). doi:10.​1007/​s10549-009-0604-x
9.
Zurück zum Zitat Chen HH, Duffy SW, Tabar L (1996) A markov chain method to estimate the tumour progression rate from preclinical to clinical phase, sensitivity and positive predictive value for mammography in breast cancer screening. The Stat 45:307–317 Chen HH, Duffy SW, Tabar L (1996) A markov chain method to estimate the tumour progression rate from preclinical to clinical phase, sensitivity and positive predictive value for mammography in breast cancer screening. The Stat 45:307–317
10.
Zurück zum Zitat Chen THH, Kuo HS, Yen MF, Lai MS, Tabar L, Duffy SW (2000) Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics 56:167–172CrossRefPubMed Chen THH, Kuo HS, Yen MF, Lai MS, Tabar L, Duffy SW (2000) Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics 56:167–172CrossRefPubMed
11.
Zurück zum Zitat Sarkeala T, Hakama M, Saarenmaa I, Hakulinen T, Forsman H, Anttila A (2006) Episode sensitivity in association with process indicators in the Finnish breast cancer screening program. Int J Cancer 118:174–179. doi:10.1002/ijc.21310 CrossRefPubMed Sarkeala T, Hakama M, Saarenmaa I, Hakulinen T, Forsman H, Anttila A (2006) Episode sensitivity in association with process indicators in the Finnish breast cancer screening program. Int J Cancer 118:174–179. doi:10.​1002/​ijc.​21310 CrossRefPubMed
12.
Zurück zum Zitat Duffy SW, Day NE, Tabar L, Chen HH, Smith TC (1997) Markov models of breast tumor progression: some age-specific results. J Natl Cancer Inst Monogr 22:93–97PubMed Duffy SW, Day NE, Tabar L, Chen HH, Smith TC (1997) Markov models of breast tumor progression: some age-specific results. J Natl Cancer Inst Monogr 22:93–97PubMed
13.
Zurück zum Zitat Anttila A, Koskela J, Hakama M (2002) Programme sensitivity and effectiveness of mammography service screening in Helsinki, Finland. J Med Screen 9:153–158CrossRefPubMed Anttila A, Koskela J, Hakama M (2002) Programme sensitivity and effectiveness of mammography service screening in Helsinki, Finland. J Med Screen 9:153–158CrossRefPubMed
14.
Zurück zum Zitat Duffy SW, Chen HH, Tabar L, Day NE (1995) Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. Statist Med 14:1531–1543CrossRef Duffy SW, Chen HH, Tabar L, Day NE (1995) Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. Statist Med 14:1531–1543CrossRef
15.
Zurück zum Zitat Kay R (1986) A Markov model for analyzing cancer markers and disease states in survival studies. Biometrics 42:855–865CrossRefPubMed Kay R (1986) A Markov model for analyzing cancer markers and disease states in survival studies. Biometrics 42:855–865CrossRefPubMed
Metadaten
Titel
Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer
verfasst von
Jenny Chia-Yun Wu
Matti Hakama
Ahti Anttila
Amy Ming-Fang Yen
Nea Malila
Tytti Sarkeala
Anssi Auvinen
Sherry Yueh-Hsia Chiu
Hsiu-Hsi Chen
Publikationsdatum
01.07.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0701-x

Weitere Artikel der Ausgabe 2/2010

Breast Cancer Research and Treatment 2/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.